Understanding Anti-IgLON5 Disease and its Outcomes

Identification, Clinical Characterization, and Prognosis of Anti-IgLON5 Disease

Observational Hospices Civils de Lyon · NCT06131346

This study is trying to learn more about Anti-IgLON5 disease by looking at how it affects sleep, movement, and overall health in people diagnosed with it.

Quick facts

Study typeObservational
Enrollment50 (estimated)
Ages18 Years and up
SexAll
SponsorHospices Civils de Lyon Academic / other
Locations1 site (Bron)
Trial IDNCT06131346 on ClinicalTrials.gov

What this trial studies

This observational study focuses on characterizing the clinical features and outcomes of patients diagnosed with Anti-IgLON5 disease, a neurological disorder linked to specific antibodies. The study aims to gather and evaluate clinical and paraclinical data from participants to better understand the disease's impact on sleep, bulbar function, and gait stability. By analyzing these data, researchers hope to clarify the immune-mediated nature of the disease and its association with certain genetic markers.

Who should consider this trial

Good fit: Ideal candidates for this study are adults over 18 years old who test positive for Anti-IgLON5 antibodies.

Not a fit: Patients who do not have Anti-IgLON5 antibody positivity or lack sufficient clinical data will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved diagnosis and management strategies for patients suffering from Anti-IgLON5 disease.

How similar studies have performed: While the specific approach of this study is novel, there is growing evidence supporting the immune-mediated pathogenesis of similar autoimmune encephalitides.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients \> 18 ans
* Anti-IgLON5 antibody positivity

Exclusion Criteria:

- Lack of clinical data

Where this trial is running

Bron

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Anti-IgLON5 DiseaseAnti-IgLON5 disease, autoimmune encephalitis, neural antibodies
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.